Core Inclusion Criteria

          1. Participant has histologically or cytologically documented diagnosis of pancreatic
             adenocarcinoma with metastatic disease. Participants with locally advanced disease are
             not eligible.

             a. Participants with recurrent locally advanced disease are eligible, provided: i. the
             last dose of chemotherapy and/or radiotherapy occurred > 4 months prior to the first
             dose of study intervention, and; ii. no systemic or radiotherapy has been administered
             in the metastatic setting.

          2. Participant must have measurable disease by RECIST v1.1.

          3. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1.

          4. A baseline tumor tissue sample is mandatory for enrollment. If archival tumor tissue
             is not available, then a fresh tumor biopsy must be provided.

        Core Exclusion Criteria

          1. Participant must not have received any prior treatment, including chemotherapy,
             biological therapy, or targeted therapy for mPDAC, with the following exceptions and
             notes:

               1. Participants who have received prior neoadjuvant or adjuvant therapy for
                  pancreatic adenocarcinoma are eligible if neoadjuvant and adjuvant therapy
                  (including chemotherapy and/or radiotherapy) was completed more than 4 months
                  before the start of study intervention.

               2. Prior surgical resection is permitted.

          2. Prior malignancy active within the previous 2 years except for locally curable cancers
             that have been apparently cured, such as basal or squamous cell skin cancer,
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

          3. Participants with an active, known or suspected autoimmune disease. Participants with:
             type I diabetes mellitus; hypothyroidism only requiring hormone replacement; a history
             of Hashimoto syndrome, within 3 years of the first dose of study intervention, which
             resolved to hypothyroidism alone; skin disorders (such as vitiligo, psoriasis, or
             alopecia) not requiring systemic treatment; or conditions not expected to recur in the
             absence of an external trigger are permitted to enroll.